Hikma Pharmaceuticals Plc
26 April 2006
Annual Information Update
LONDON, 26 April 2006. In accordance with Prospectus Rule 5.2, Hikma
Pharmaceuticals PLC ('Hikma' or 'the Company')(LSE: HIK) sets out below a
summary of the information which has been published or made available to the
public over the previous 12 months. The information referred to in this Update
was up to date at the time the information was published, but some information
may now be out of date.
Stock Exchange announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may
be viewed and downloaded from the London Stock Exchange website
(www.londonstockexchange.com/marketnews) or from the press releases page on the
Company's website at (http://investors.hikma.com/hikma/regulatorynews.jsp). The
Stock Exchange announcements made during the defined period are:
Date of announcement Headline of announcement
25 Apr 2006 Hikma to list Global Depository Receipts on DIFX
21 Apr 2006 Notification of Transaction
19 Apr 2006 Hikma acquires JPI
03 Apr 2006 Block listing
29 Mar 2006 Hikma Preliminary Results
25 Jan 2006 Hikma Announces FDA Approval
23 Jan 2006 Trading Statement
05 Dec 2005 Director/PDMR Shareholding
30 Nov 2005 Over allotment option
28 Nov 2005 Renewal of Contract
04 Nov 2005 Director/PDMR Shareholding
02 Nov 2005 Publication of Prospectus
01 Nov 2005 Stabilisation Notice
01 Nov 2005 Pricing Announcement
17 Oct 2005 Hikma Pharmaceutials announces intention to float
Documents filed with the Financial Services Authority
The company has filed the following documents with the Financial Services
Authority ('FSA') over the previous 12 months. These documents are or will be
available to be viewed via the FSA's Document Viewing Facility or at the
Company's registered office.
Date filed with the FSA Document filed with the FSA
26 Apr 2006 Annual report and accounts
26 Apr 2006 Notice of Annual General Meeting
01 Nov 2005 Prospectus
Documents filed with Companies House
The Company has made the following filings with Companies House. Copies of these
documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14
3UZ or, if you are a registered user, they may be viewed and downloaded using
Companies House Direct at www.direct.companieshouse.gov.uk. The Companies House
filings made during the defined period are:
Date filed with Document filed with Companies House
Companies House
26 Apr 2006 2005 Annual report and accounts
26 Apr 2006 Notice of Annual General Meeting
13 Feb 2006 Form 123 - Notice of increase in share capital
13 Feb 2006 Form 122 - Notice of sub-division
13 Feb 2006 Authorisation of allotment of securities
17 Jan 2006 Form 288a - Director appointed
29 Nov 2005 Form 288a - Director appointed
29 Nov 2005 Form 288a - Director appointed
29 Nov 2005 Form 288a - Director appointed
07 Nov 2005 Adoption of Memorandum of Association and Articles of
Association
28 Oct 2005 Company name change
23 Sep 2005 Approval of change of rights of all shares
23 Sep 2005 Memorandum of Association and Articles of
Association
19 Sep 2005 Company name change
22 Sep 2005 Form 288a - Director appointed
22 Sep 2005 Form 288a - Secretary appointed
22 Sep 2005 Form 288a - Director appointed
22 Sep 2005 Form 288a - Director resigned; Secretary resigned
22 Sep 2005 Form 288a - Director resigned
22 Sep 2005 Form 225 - Change of accounting reference date
16 Sep 2005 Authorisation to commence business and borrow
16 Sep 2005 Form 117 - Application to commence business
08 Sep 2005 Incorporation documents
In addition, the Company filed Forms 88(2) - Return of Allotment of Shares with
Companies House. These were posted on the Companies House Direct website on 13
February 2006 and 22 September.
Henry Knowles
Company Secretary
27 April 2006
- ENDS -
Enquiries:
Hikma Pharmaceuticals plc +44 20 7479 4870
Henry Knowles, Company Secretary +44 20 7479 4893
Susan Ringdal, Investor Relations Director
Brunswick Group LLP +44 20 7404 5959
Jon Coles / Wendel Verbeek / Justine McIlroy / Alex
Tweed
Notes to Editors
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.